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The main pharmacological aspects of pharmacodynamics (PD) and pharmacokinetics (PK) of aspirin as antiplatelet agent were
unravelled between the late sixties and the eighties, and low-dose aspirin given once daily has been shown to be a mainstay in
the current treatment and prevention of cardiovascular disorders. Nevertheless, several PD and PK aspects of aspirin in selected
clinical conditions have recently emerged and deserve future clinical attention. In 1994, the term “aspirin resistance” was used
for the ﬁrst time, but, until now, no consensus exists on deﬁnition, standardized assay, underlying mechanisms, clinical impact,
and possible eﬃcacy of alternative therapeutic interventions. At variance with an undeﬁned aspirin-resistant status, in the last 5
years, the concept of variability in response to aspirin due to speciﬁc pathophysiological mechanisms and based on PK and/or
PD of the drug has emerged. This growing evidence highlights the existence and possible clinical relevance of an interindividual
variability of pharmacological aspirin response and calls for new, large studies to test new low-dose aspirin-based regimens which
mayameliorateplateletacetylation,reducevariabilityindrugresponsiveness,andimproveclinicaleﬃcacyonselectedpopulations.
1.Introduction
In 1982, the Nobel Prize in Physiology or Medicine was
awarded jointly to Sune K. Bergstr¨ om, Bengt I. Samuelsson,
and John R. Vane for their discoveries during the sixties
and early seventies of prostaglandins and related biolog-
ically active substances. They also showed that aspirin
and aspirin-like drugs inhibited prostaglandin biosynthesis
from arachidonic acid (AA) and that this was the basis
for their therapeutic anti-inﬂammatory, antipyretic, and
analgesic eﬀects [1, 2]. The initial descriptions of a platelet-
inhibiting eﬀect of aspirin in the late sixties were based on
assays of hemostasis and platelet function available at that
time, such as the bleeding time and ADP-induced optical
aggregation [3, 4]. On the basis of those assays, aspirin
was described as a weak antiplatelet agent, causing a “mild
prolongation of the bleeding time” and a “minor hemostatic
defect” in normal subjects [3–5]. Few years later, Smith
and Willis demonstrated that aspirin was able to block
prostaglandin production from human platelets [6], and the
group of Samuelsson identiﬁed thromboxane (TX) A2 as
the biologically active prostanoid synthesized from AA in
activated platelets and blocked by aspirin [7].
In the mid seventies, P. Majerus and collaborators
unravelled the mechanism of action of aspirin at the molec-
ular level. Using proteins puriﬁed from human platelets
and aspirin radiolabelled in the acetyl residue (3H-acetyl
aspirin), they showed that aspirin rapidly (within minutes)
and irreversibly acetylated a speciﬁc protein fraction of
approx. 85kDa within the AA-binding, active site, and this
protein corresponded to human cyclooxygenase (COX) [5,
8, 9]. Aspirin acetylated the 85kDa platelet’s fraction in
a saturable manner and at concentrations relatively lower
(up to 30μM) than the ones required to acetylate other
puriﬁed proteins such as albumin, immunoglobulins, or
ﬁbrinogen [5]. Moreover, diﬀerent groups reported that
COX in intact platelets was acetylated or inhibited in vitro by
aspirin concentrations lower than the ones required in other
nucleated cellular systems (human synovial tissue, smooth
muscle cells, ﬁbroblasts, and sheep seminal vesicles) [5, 9,
10], indicating a possible, cell-milieu-dependent modulation
of the enzymatic COX activity. Approximately twenty years2 Thrombosis
later, P. Loll and coworkers resolved the X-ray crystal
structure of COX-1 bound to aspirin [11].
Thepharmacokinetics(PK)oforalaspirininhealthyvol-
unteers, especially in a wide dose range, including low doses
(between 25 and 160mg/day), was described soon thereafter
by diﬀerentgroupsinEuropeandintheUnitedStates[8,12–
15]. The description of aspirin PK was very much facilitated
by an ex vivo method introduced by C. Patrono and col-
laborators, reﬂecting the entire enzymatic COX-dependent
activity of platelets in the peripheral blood [13]. In fact, until
that time, methods for studying aspirin inhibition ex vivo in
humans were quite laborious and used an in vitro mixing of
3H-acetyl aspirin and blood from aspirin-treated subjects [8,
9], or on TXB2 measured in aggregated platelet-rich plasma
[14]. These methods required relatively large amounts of
blood, platelet isolation, extraction of protein fractions, or
aggregation reactions and were time consuming and scarcely
applicable to large-scale studies. Moreover, the method with
3H-acetyl aspirin explored the degree of acetylation of
platelet’s COX protein by aspirin, but it did not measure
the level of inhibition of COX enzymatic activity leading to
TXA2 generation. The method described and validated by
Patrono and collaborators required minimal blood volume
and little preanalytical handling and was relatively rapid. It
was based on a physiological hemostatic reaction: during
whole blood clotting at 37◦C, endogenous thrombin is
physiologically generated. Thrombin is one of the strongest
trigger of platelet’s AA release [16], maximally fuelling the
enzymatic activity of COX and the subsequent biosynthesis
of TXA2 in platelets (Figure 1). TXA2 is extremely labile
in an aqueous milieu and is nonenzymatically hydrolyzed
to TXB2, which is a stable derivative and measurable in
serum by immunometric assays without puriﬁcation steps
[13]. Thus, this biochemical method closely reﬂects the
maximal biosynthetic capacity (and its degree of inhibition)
of platelet’s COX enzyme in a physiological environment,
such as whole blood and endogenous thrombin.
The pharmacology of aspirin in humans, especially in
the low-dose range, was described by those methods, and its
maincharacteristicscanbesummarizedasfollows.Theeﬀect
of aspirin repeatedly administered once daily is irreversible,
cumulative, saturable, reaching a ceiling eﬀect in the low-
dose range, for instance, at approximately 100mg of plain
aspirin in single dose or 20–40mg for repeated (approx
10 days) daily dosings [12, 13]. Aspirin acetylates platelet’s
COX-1 already in the presystemic, portal blood, before the
liver ﬁrst pass [15]. Finally, the time course of a nearly
complete platelet cyclooxygenase inhibition by repeated low
doses, and conversely, the time course of the recovery of
platelet COX activity after aspirin withdrawal takes approxi-
mately 7–10 days, reﬂecting two characteristics of platelets:
their almost-complete inability to replace the acetylated
enzyme and their lifespan [9, 12–14]. Moreover, following
aspirin withdrawal, even after lower doses, diﬀerent studies
showed a two-day lag before the appearance of a signiﬁcant
new, nonacetylated COX protein or COX enzymatic activity
in circulating platelets [8, 13]. This delay was observed
independently of the techniques used (radiolabelled aspirin
and serum TXB2), and it likely reﬂects the acetylation of
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Figure 1: Cyclooxygenase-dependent arachidonic acid pathway in
platelets. Thrombin, generated in vivo or ex vivo by several chemical
or physical stimuli, activates its protease-activated receptors (PARs)
increasingintraplateletcalcium,whichtriggersphospholipases(PL)
A2-dependent cleavage of arachidonic acid (AA) from plasma
membranes. AA is the enzymatic substrate of cyclooxygenase
(COX)-1 and -2. COX-1-dependent AA path in platelets generates
mainly TXA2 which ampliﬁes platelet activation by binding to its
platelet receptors (TPs). COX-2-dependent AA path in normal
platelets is less prominent and generates mainly PGE2 which acts
as a positive modulator of platelet response to other agonists by
bindingtoitsplateletreceptors(EPs).TXA2 bothinvivoorexvivois
nonenzymatically hydrolized to TXB2, which is biologically inactive
but stable, and can be measured in ex vivo assays or undergoes
further hepatic enzymatic biotransformation in vivo.
megakaryocytes, which, at least in conditions of normal
megakaryopoiesis, during the ﬁrst 24–48 hour after aspirin
withdrawal, largely release in the peripheral blood platelets
withacetylated,nonfunctioningCOXenzymes[8,13].These
data were conﬁrmed in a more recent study [17]. This
lag interval has also been reported in diﬀerent mammalian
species [18, 19], compatibly with the species-speciﬁc kinetics
of megakaryopoiesis.
Following the description of low-dose aspirin PK, the
clinical beneﬁts of 160mg once daily (enteric coated formu-
lation) was tested for the ﬁrst time on a large number of
acute myocardial infarction (MI) patients in the ISIS-2 trial
[20]. In that trial, aspirin reduced by approximately 25% the
vascular death in acute MI patients as compared to placebo.
A meta-analysis of the antiplatelet’s trialist’s collaboration
of clinical trials on high-risk populations showed that the
cardiovascular protection of aspirin is “saturable” at daily
doses of aspirin between 75 and 160mg day [21], similarly to
the dose range which reaches the ceiling eﬀect in inhibiting
serum TXB2 [13]. Daily doses beyond 160–325mg day do
not add clinical beneﬁt, versus placebo, while increase the
bleeding risk and are associated with a trend in a reduction
of cardiovascular protection, presumably reﬂecting the inhi-
bition of prostacyclin in the vessel wall [21, 22].
2. From AspirinResistance to Variabilityin
Responsiveness
Practicing physicians have long recognized that individual
patients show wide variability in response to the same drugThrombosis 3
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Figure 2: Pharmacokinetics, pharmacodynamics and pathophysiological conditions aﬀecting the clinical outcome of a drug. The
ﬁgure depicts the diﬀerent pharmacokinetics and pharmacodynamics steps possibly involved in drug transformation and clinical eﬀect.
Pathophysiological conditions which may aﬀect both PK and/or PD are also reported in the ﬁgure. This ﬁgure is modiﬁed from [24].
Table 1: Main pharmacological features of drug resistance versus variability in drug response.
Resistance Variability
(i) is usually triggered by drug exposure, slowly reversible, and
often drug speciﬁc
(i) not induced by and often independent of the drug, can aﬀect
diﬀerent drugs, and does not revert upon withdrawal
(ii) implies a change of the drug target making it inaccessible or
no longer inhibitable (ii) the drug target is not necessarily modiﬁed or inaccessible
(iii) detectable by speciﬁc laboratory tests, which impact on the
clinical decision of changing drug
(iii) laboratory tests are of little help in therapeutic decisions if
mechanism(s) are unknown (change drug, increase dose, more
frequent intake?)
ortreatment.Theconceptofinterindividualvariabilityinthe
responsetoanydrugcanbeexempliﬁedasfollows:arangeof
drug plasma concentrations is often required to produce an
eﬀect of a speciﬁed intensity in all the patients; on the other
hand, at a speciﬁed plasma drug concentration, an eﬀect of
varying intensity will occur in diﬀerent individuals. Drug’s
PK encompasses drug absorption, distribution, metabolism
(biotransformation), and elimination, thus contributing to
the quite variable plasma concentrations of the drug and/or
its active metabolite(s) in diﬀerent individuals receiving the
same dose. Pharmacodynamics (PD) refers to the biochem-
ical and physiological eﬀects of drugs and their mechanisms
of action, which result in a complex relationship between
a given concentration and the magnitude of the observed
clinical response [23]. Drug’s PK and PD encompass the
majority of sources of inter- and intraindividual variability
in drug response (Figure 2) and are the basis to under-
stand any treatment success, failure, or adverse reactions.
Recommended dosage regimens are usually designed for
an “average” patient, but adjustments may be required by
speciﬁc diseases or physiological factors.
Drug resistance, a well-characterized phenomenon in
the ﬁeld of chemotherapy, is only one possible cause of a
modiﬁed (variable) response to a drug [23]. Usually, drug
resistance pertains to the PD of a drug (direct or indirect
changes in drug-target interaction), is drug-induced, and is
stable over time once it has been triggered and obliges to
treatment interruption [29]. The main features of variability
versus resistance are depicted in Table 1. At variance with
any other class of drugs, the characterization of “aspirin
resistance”, escaped any well-established pharmacological
deﬁnition or mechanism [30–32]. Aspirin resistance has
been heterogeneously deﬁned on a clinical basis as treatment
failure and/or on a functional basis as lower-than-expected
responsiveness to diﬀerent, nonstandardized platelet func-
tional assays [30–32]. However, agreement between diﬀerent
platelet functional assays is less than optimal, percentage
of resistance is very much assay dependent, studies on
“resistance” are mainly retrospective and not controlled for
compliance or NSAID intake [17, 33, 34]. Thus, aspirin
“resistance” still lacks consensus on deﬁnition, reference
assay, pathogenetic mechanisms, and, unlike a true drug
resistance, is very often an unstable phenotype over time [17,
30]. An aspirin-induced, time-dependent change in aspirin’s
target (e.g., COX-1 and/or -2), as shown for antibiotic or
antiblastic resistance, identiﬁed by a standardized assay and
successfully treated with a diﬀerent antiplatelet agent, has
never been reported. Thus, no pharmacological, evidence-
based strategies can be rationally applied to understand and
treat a “resistant” patient.4 Thrombosis
Salicylic 
acid
(inactive)
Ser 529– 
COX-1 
(inactive)
COOH
HCE2
acetic acid
Salicylic acid 
(inactive)
Phase II 
conjugation
Glucuronide, 
glycine conjugates
(kidney excretion)
Portal
blood
Platelets
Systemic
bioavailability ~50%
Bone-marrow MKs
Portal blood
COOH COOH
OH Aspirin
(acetylsalicylic acid)
Liver
(ﬁrst-pass effect)
COOH
Salicylic acid
(inactive)
Ser 529– Ser 529–
OH
Stomach and
small intestine
HCEs
Salicylic acid 
(inactive)
Plasma esterases
Salicylic acid 
(inactive)
Plasma esterases
COX-1  
(active)
COOH
OH
COOH
OH
COOH
OH
COX-1  
(active)
COX-1 
(inactive)
COOH COOH
OH OCOCH3
OCOCH3
OCOCH3
OCOCH3
OCOCH3
OCOCH3
Ser 529–OH
COOH+ CH3
Figure 3: Pharmacokinetics of aspirin. Aspirin is absorbed in the stomach and small intestine, exerts its pharmacodynamic eﬀect, for
instance, the acetylation of a Serine (Ser) 529 residue of COX-1 already in the portal blood, and is biotransformed to inactive salicylic acid by
intestine, plasma, and liver esterases. On average, its systemic bioavailability is approx. 50% of the administered dose. Once in the systemic
circulation, aspirin reaches bone-marrow megakaryocytes (MKs) and inhibits COX-1 and -2 of MKs and developing platelets. HCE: human
carboxylesterase.
At variance with an undeﬁned “resistance”, as for any
other drug, aspirin responsiveness in diﬀerent patients
can be varied by physiological or pathological conditions
aﬀecting drug’s PK or PD mechanisms. Thus, in 2005, a
diﬀerent concept surfaced on aspirin treatment, for example,
the possibility of PK- or PD-based variability in aspirin
responsiveness of the individual patient [24, 35, 36].
3.Pharmacokinetic and/orPharmacodynamic
SourcesofVariabilityinAspirinResponse
As compared to other antiaggregants, the PK of aspirin
is quite straightforward (Figure 3). Plain aspirin is rapidly
absorbed by passive diﬀusion as undissociated salicylic acid
from the stomach, where the pH is low and hydrolysis is
minimal, and from the upper small intestine. Oral bioavail-
ability of acetylsalicylic acid is approximately 50% because a
fraction of the administered and absorbed dose of the drug
is inactivated, that is, deacetylated, by the carboxylesterases
in plasma and liver before entering the systemic circulation
(ﬁrst-pass eﬀect). The hepatic human carboxylesterase-2
(HCE2) isoform is mainly involved in the ﬁrst-pass aspirin
bioinactivation as compared to the HCE1 isoform [37, 38].
Inactivation may also occur in the gut by means of the
same esterases. Furthermore, aspirin can be hydrolized in
the peripheral blood by some plasma cholinesterases [39],
erythrocyte arylesterases [40], and other esterases called
“aspirin esterases” [39]. After a single oral dose of plain
aspirin, plasma peak is reached in approximately 1 hour, its
plasma t1/2 is 20 minutes [41]. The PD of aspirin pertains
its interaction with and blockade of the active site of COX-
1 and/or -2, being aspirin a nonselective inhibitor of both
COX-1 and -2 isoforms. The main site of platelet’s COX
acetylation in the low-dose range of aspirin is portal blood,
before the ﬁrst-pass eﬀect [15].
Aside from compliance, which is a critical issue especially
in chronic patients [42], possible sources of variability in
aspirin responsiveness due to modiﬁcation of its PK and/or
PD might be aspirin formulations, body size, ageing, drug-
drug interaction, and rate of the drug target turnover, for
example, platelet’s COX-1 and -2.Thrombosis 5
Table 2: Relative risk of incomplete (<95%) inhibition of TXB2 for a 10kg increase in body weight.
Preparation RR per 10kg weight increase 95% CI
Asasantin b.i.d. (25mg ASA plus 200mg dipyridamole) 1.9 1.3–2.7
EC aspirin (75mg) 2.2 1.7–3.0
Abbreviations: ASA: aspirin; EC: enteric coated. This table is modiﬁed from [26].
Table 3: Age-related plasma esterase activities.
Type of esterase 18–29yrs 30–44yrs 45–69yrs 60–75yrs >75yrs >75 “fraile”
Ach esterase 2.78 ±0.43 .35 ±0.13 .1 ±0.23 .3 ±0.23 .13 ±0.31 .96
∗ ±0.6
Aspirin esterase 162 ±27 161 ±18 146 ±11 147 ±10 128 ±22 64
∗ ±23
Correlation age-esterase activities: Ach r =− 0.011, P = 0.9; ASA r =− 0.25, P = 0.11; Ach: acetylcholine; yrs: years; ∗P<0.005 versus nonfraile, old people.
Data from [27, 28].
Enteric-coated (EC) aspirin formulations, now widely
used in cardiovascular disease prevention and treatment,
have been conceived on the hypothesis of resisting the disin-
tegration of the pill in the acid environment of the stomach,
thus releasing the drug into the upper small intestine, and
avoiding a local damaging eﬀect of acetylsalicylic acid in
the stomach [43]. However, evidence supporting a better
gastrointestinalsafetyofECaspirinareinconclusive[44–46].
Moreover, in the upper small intestine a slower absorption, a
more alkaline milieu, and the activity of intestinal HCE may
facilitate hydrolysis to salicylate (Figure 3), thus lowering the
bioavailability of aspirin from EC formulations. In agree-
ment with this hypothesis, diﬀerent groups have reported an
incomplete serum TXB2 suppression in a fraction of subjects
exposed to EC as compared to plain aspirin formulations
[26, 47]( Table 2). Given that some studies administered to
the same subjects diﬀerent aspirin formulations and that
subjects fully inhibited by plain aspirin were incompletely
responsive to diﬀerent EC formulations, a PD cause of an
incomplete acetylation of platelet COX-1 associated with EC
preparations can be ruled out. Thus, a diﬀerent PK due to a
variable absorption and bioavailability of EC formulations
both presystemically and systemically, is likely. Moreover,
whether a reduced bioavailability of EC formulation might
lower the antithrombotic protection of aspirin especially
at lower doses remains unproven. It may be conceivable
that EC aspirin, especially when associated with conditions
characterized by additional modiﬁcations of aspirin PK such
as obesity, might aﬀect the antithrombotic protection of the
drug (Table 2).
Obesity is known to aﬀect the PK of several classes of
drugs such as chemotherapies, psychotropic drugs, anaes-
thetics, opioids, and β-blockers [48, 49] due to a change
in body composition, regional blood ﬂow, modiﬁcation
of plasma proteins and/or tissue components, distribution
volume, and kidney and hepatic clearance mechanisms.
Moreover, in obese subjects, the activity of some CYP450s
and phase II conjugation enzymes are increased, human
adipose tissue upregulates HCE1 [50]. The PK of markedly
lipophilic drugs is particularly aﬀected by obesity as com-
pared to less lipophilic ones [49]. Modiﬁcation of PK
mechanism(s) associated with obesity might contribute to
a faster bioinactivation of aspirin inside and outside the
liver. In fact, aspirin is a highly lipophilic molecule, and
it is biotransformed by phase II conjugation (Figure 3).
Consistently, an increased body weight has been associated
with a lower biochemical responsiveness to aspirin, as
assessed by TXB2 or platelet function assays [47, 51, 52]
(Table 2), and with a possible lower clinical eﬃcacy of
low-dose aspirin [53] although the clinical impact of this
phenomenon has never been formally tested in large trials.
Ageing is also associated with a modiﬁed, usually
increased, drug responsiveness. The most important PK-
related changes in old age include a decrease in the excretory
capacity of the kidney and a decline in hepatic blood
ﬂow, hepatocyte mass, and consequent reduced hepatic
drug bioinactivation [54]. In addition, comorbidities and
polypharmacy are often interfering with drug response. A
reduction of aspirin esterase and cholinesterase activity in
frail elderly people has been reported [27, 55]( Table 3).
For some drug classes, such as β-blockers and opioids, age-
dependent PD changes have been described [55]. The elderly
appear also more susceptible to drugs aﬀecting hemostasis,
a lower dose of warfarin is needed to reach the same
therapeutic window in old versus younger patients, and it
is associated with a higher bleeding tendency [55]. As far
as aspirin is concerned, old people appear more sensitive
(and responsive) to aspirin as compared to younger ones,
measured as a degree of TXB2 inhibition, [51]. Moreover,
gastrointestinal bleeding risk in aspirin-treated patients
steeply increases in the older decades of life [56, 57]. From
aP Dp o i n to fv i e w ,s e r u mT X B 2 and platelet aggregation
induced by arachidonic acid do not change with age in
untreated healthy subjects [58, 59], possibly ruling out
an age-related change in the aspirin’s PD. Whether these
biochemical data might aﬀect the beneﬁt/risk proﬁle of
aspirin in older subjects is unknown. The elderly generally
have been underrepresented in clinical trials, creating many
uncertainties and less optimal medical care. Ongoing trials
are addressing the issue of aspirin risk/beneﬁt proﬁle in the
elderly. The Japanese Primary Prevention Trial (JPPP) has
completedin2007theenrolmentof14,460high-riskpatients
aged between 60 and 85yrs [60]. Patients are randomised to
placeboorECaspirin100mg/day,andtheprimaryendpoint
of this study is a composite of cardiovascular events. The
Aspirin in Reducing Events in the Elderly (ASPREE) is also a6 Thrombosis
primary prevention, placebo-controlled study, assessing the
eﬃcacy of daily 100mg EC aspirin in reducing death from
any cause, incident dementia or persistent physical disability
in subjects aged ≥70yrs, including also subjects without
additional risk factors, aside from age [61].
Some NSAIDs might create a transient status of reduced
responsiveness to aspirin, due to a PD competition between
the short-lived aspirin and some NSAIDs which have a
relatively longer half-life, for the same Arg residue at the
COX-1 active site [62]. Due to the over-the-counter access
to these drugs and to the fact that NSAIDs are the most used
drugs worldwide [63], it is hard to estimate the impact of
this phenomenon in reducing eﬃcacy and safety of aspirin’s
cardiovascular prevention. Recently, a large retrospective
nationwide study showed that PPI use is associated with
an increased risk in cardiovascular events in aspirin-treated
patients [64]. It is unknown whether this eﬀect is due to a
PKdrug-druginteraction,wherePPIs,byincreasingstomach
pH, reduce aspirin’s bioavailability, or there is an increased
risk of cardiovascular events associated with the class of PPIs
[65].
Platelet turnover was hypothesized to inﬂuence the
response to aspirin already more than 25 years ago. A
pathophysiologicalconditionofincreasedplateletgeneration
is essential thrombocythemia (ET), a myeloproliferative
neoplasm characterized by increased arterial thrombotic
complications (myocardial infarction, stroke, or transient
ischemic attack) [66], thus requiring antiplatelet treatment
of prophylaxis. Previous studies from our group reported
that aspirin-treated (100mg once daily) patients aﬀected
by myeloproliferative neoplasms, and, more speciﬁcally, by
ET, had a signiﬁcant residual, uninhibited serum TXB2 [25,
67, 68]. While low-dose aspirin given once daily is capable
of inhibiting by approximately 97% to 99% platelet TXA2
biosynthesis in healthy subjects [13, 17], the same aspirin
regimen is unable to fully inhibit platelet TXA2 production
in approximately 80% of ET patients [25]. The residual
platelet COX (both COX-1 and -2) could be fully suppressed
to levels comparable to controls by adding aspirin in vitro
[25], thus indicating the presence of unacetylated platelet
enzyme in at least a fraction of peripheral platelets (Figure 4)
and ruling out changes in the drug target (platelet COX-
1 and -2) which make it inaccessible or scarcely inhibitable
by aspirin. Whether incomplete suppression of platelet COX
activity in ET is due to disease-related changes in PK or
PD of once-daily low-dose aspirin is currently unknown.
Changes in aspirin PK in ET seem improbable due to the
relatively young age of the patients, thus obesity, diabetes,
other comorbidities, or polypharmacy are unlikely. On the
other hand, due to a faster renewal of aspirin’s drug target
consequent to an enhanced platelet turnover, a disease-
relatedPDchangeisbothbiologicallyandpharmacologically
plausible. Thus, an accelerated platelet turnover might gen-
erate more unacetylated COX-1 and/or COX-2 during the
24-hour dosing interval, which would account for a partial
recovery of TX-dependent platelet function, for example, the
interval between two subsequent aspirin intakes.
Another disease associated with a lower-than-expected
response to antiplatelet agents is type 2 diabetes mellitus
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Figure 4: Serum TXB2 production from low-dose aspirin-treated
patients with essential thrombocythemia ex vivo and after in vitro
incubation of additional aspirin. Box-whisker plots of serum TXB2
values from 14 patients chronically treated with 100mg/die aspirin,
without (vehicle) and with in vitro incubation with 50μM aspirin.
∗P<0.001. This ﬁgure is modiﬁed from [25].
(T2DM). Aspirin is currently recommended for T2DM
independently of prior vascular complication [69, 70].
However, direct evidence for its clinical eﬃcacy and safety in
this setting is lacking [71, 72]o ra tb e s ti n c o n c l u s i v e[ 73, 74].
Once-daily administration of low-dose aspirin (75–100mg)
may be associated with incomplete inhibition of platelet
COX-1 activity [75] and TX-dependent function [76, 77]i n
diabetics. PD or PK-related mechanisms might contribute
to a reduced response in T2DM. Both in humans and
animal models, diabetes is characterized by increased mean
platelet volume, increased platelet mass, platelet turnover,
and by morphological hallmarks of abnormal megakary-
opoiesis [78–80]. Increased platelet turnover and abnormal
megakaryopoiesis in T2DM might depend of diabetes itself
or be secondary to an increased platelet consumption,
likely at atherosclerotic lesions. However, previous reports
on humans or animals suggest a primary disturbance of
megakaryocytes in diabetes [80, 81]. Plasma aspirin esterases
do not appear to be modiﬁed by T2DM [82]. Another
PK-based mechanism reducing aspirin responsiveness in
a fraction of patients might be obesity, often associated
with T2DM, which may limit the antiplatelet eﬀect of
aspirin as shown in nondiabetic obese subjects. Another
mechanism might be related to enhanced formation of lipid
hydroperoxides limiting COX-isozyme acetylation by aspirin
[83] in both megakaryocytes and circulating platelets.
4. How to RestrainInterindividualVariability
inResponse to Aspirin?
Lower responsiveness to aspirin can be a ﬁnal, common
phenotype, resulting from diﬀerent PK- and/or PD-related
mechanisms.EventhoughtheﬁnalbiochemicalphenotypeisThrombosis 7
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Figure 5: Models of variable responsiveness to low-dose aspirin given once daily. The ﬁgure depicts models of pharmacodynamic- (PD-) or
pharmacokinetic- (PK-) related variable pharmacological response to aspirin, as measured by serum TXB2. Under normal conditions (left
panel) aspirin inhibits peripheral platelets and bone-marrow megakaryocytes (MKs) resulting in a relatively steady inhibition of platelet
COX activity over the 24 hour dosing interval. In case of increased platelet turnover (mid panel), the short-lived aspirin appears unable to
acetylated new platelets which are released from MKs during the 24 hour dosing interval, thus resulting in a progressive increase in TXA2
generation between 12 and 24 hours after dosing. In case of variation in drug’s PK (right panel), a reduced drug bioavailability in the portal
and/or in the systemic circulation would lead to a suboptimal platelet TXA2 generation already at early time points (6–12 hours) after drug
intake. Unacetylated platelets are represented in green. EC: enteric coated.
apersistent,residualTXA2 generationfromplateletsnotade-
quately inhibited by aspirin, understanding the underlying
PK- or PD-related mechanisms is crucial to design strategies
able to restore a normal response, restrain variability, and
tailor the therapeutic intervention to the therapeutic need.
Consistently with the hypothesis of a change in aspirin’s
PD on the basis of accelerated platelet turnover in T2DM, a
substantial recovery of serum TXB2 between two subsequent
low-dose aspirin dosing, for example, between 12 and 24
hours after aspirin intake, has been recently reported by our
group [84] in a fraction of aspirin-treated T2DM patients.
Similarly, in approx. 30% of stable coronary artery disease
patients, a faster recovery of AA-dependent platelet function,
measured 24 hours after dosing was associated with diabetes,
smoking,andinﬂammatorybiomarkers[85,86].Thus,some
patients who are fully responsive to aspirin up to 6–12
hours after drug intake, ruling out PK modiﬁcations, show
a substantial recovery of platelet’s cyclooxygenase activity
within the interval between dosing, for example, 24 hours.
Thus, PD-related mechanisms, such as an increased platelet
turnover or intraplatelet neosynthesis of COX-1 and/or -2
within 24 hours after dosing, have been hypothesized [84–
87]. Consistently with this, hypothesis in a small group
of healthy subjects, higher residual serum TXB2 while on
aspirin was associated with the highest tertile of reticulated
platelets, which are the youngest circulating platelets [88].
To correct the reduced responsiveness to aspirin in
ET or T2DM, small randomized studies tested diﬀerent
strategies, such as increased dose and/or more frequent
drug administration. Almost simultaneously, P. Hjemdahal’s
and our groups have recently presented two studies in
T2DM, with slightly diﬀerent design and measurements
(arachidonic-acid induced platelet aggregation or serum
TXB2), both showing that a twice-daily low dose aspirin (75
or 100mg) achieved an almost-complete and steady 24-hour
platelet inhibition as compared to a single administration
of a aspirin double dose (320 or 200mg daily) [84, 87]. In
both studies, reticulated platelets (RP) and/or mean platelet
volumes (MPV) measured as indexes of increased platelet
turnover were signiﬁcantly correlated with a worse aspirin
responsiveness. The eﬀectiveness of a twice-daily dosing
ratherthanofadoubledoseinreducingresidualserumTXB28 Thrombosis
or other platelet-related indexes is more consistent with a
PD-, platelet turnover-based mechanism rather than with a
lowerbioavailabilityofaspirin.Thus,providedthatlow-dose
aspirin PK is preserved and the drug target molecule is not
changed(e.g.,oxidativelydamagedorstructurallymodiﬁed),
then in conditions of accelerated megakaryopoiesis, a more
frequent, rather than a higher doses might be needed and
tested in large, randomized studies.
On the other hand, if aspirin PK is modiﬁed, without
any change in platelet turnover and drug target PD, as
possibly the case in obese subjects for reduced bioavailability
of the drug, then a dose increase might be suﬃcient to
restore an aspirin-responsive phenotype. In a small study,
doubling the once-daily aspirin dose in obese subject (from
75 EC to 150 plain formulation, mean body weight 120kg)
restored a nearly complete inhibition of serum TXB2 [47].
Thus, if a lower aspirin bioavailability is associated with
obesity, without changes in aspirin PD, then one would
expect that a small increase of the dose, within the low-
dose range (<325mg od), might be able to restore a normal
pharmacological response to the drug. A model is depicted
in Figure 5.
5. Conclusions
Aspirin within the low-dose range, administered mostly
once daily, is the main antiplatelet drug for cardiovascular
disease treatment, reducing on average by approximately
30% major cardiovascular events, especially MI, in high-
risk patients. A substantial individual variability in bio-
chemical drug responsiveness can be associated with speciﬁc
physiologic (ageing), pathologic (ET, T2DM), or pharmaco-
logic (NSAIDs, PPIs?) conditions due to transient (NSAID
interaction and obesity) or stable (ET, T2DM, and ageing)
changesinaspirin’sPKand/orPD.Diﬀerentaspirinregimens
within the low-dose range, in small studies, have been able
to restore a normal aspirin pharmacological responsiveness.
Whether this variability can aﬀect the clinical eﬃcacy and
safety of aspirin in cardiovascular prevention, especially in
some primary prevention settings (T2DM), and the risk-
beneﬁt proﬁle of alternative ways of giving aspirin are the
next challenges in the aspirin scenario.
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